Noema Pharma

Noema Pharma is a Swiss-based company dedicated to treating orphan neurological diseases characterized by neuronal imbalance. The company is developing four clinical mid-stage therapeutic products licensed from Roche, with strong safety profiles. The lead product, NOE-101, is an mGluR5 inhibitor that has entered Phase 2b trials for two indications: refractory seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN). The PDE10A inhibitor, NOE-105, is being prepared for Phase 2b trials to treat Tourette Syndrome. The company is conducting validation studies on two additional clinical-stage assets, the mGluR2/3 inhibitor NOE-109 and the triple reuptake inhibitor NOE-115, for undisclosed indications.